Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Silybum marianum extract** refers to extracts derived from the seeds and/or fruits of the Silybum marianum plant (milk thistle). The principal active constituent is **silymarin**, a complex of flavonolignans primarily including silybin (silibinin), silydianin, silychristin, isosilybin, and their associated isomers. Silymarin exhibits **antioxidant**, **anti-inflammatory**, **immunomodulatory**, **antifibrotic**, and **antiproliferative** effects. Its hepatoprotective activity is attributed to free radical scavenging, increasing glutathione content, inhibiting lipid peroxidation, stabilizing cell membranes, and modulating nuclear receptors and cell transporters. Silymarin is known to modulate cytokine signaling (such as TNF-α, IL-2, IL-4, IFN-γ), inhibit apoptosis, and upregulate ribosomal protein synthesis via stimulation of RNA polymerase I. Therapeutic applications primarily include **supportive management of liver disorders** (e.g., cirrhosis, hepatitis, toxin/drug-induced hepatotoxicity), glycemic control in type 2 diabetes, and adjunctive use in mushroom poisoning. The product is considered safe at physiological doses, with rare side effects predominantly gastrointestinal[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silybum marianum extract.